What is the right dose? The elusive optimal biologic dose in phase I clinical trials

Research output: Contribution to journalEditorial

46 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)4054-4055
Number of pages2
JournalJournal of Clinical Oncology
Volume24
Issue number25
DOIs
StatePublished - Sep 1 2006

Fingerprint

Drug Dose Response Relationship
Drug Administration Schedule
Indoles
Clinical Trials, Phase I
Protein Kinase Inhibitors
Antineoplastic Agents
Protein Kinase C
Multicenter Studies
Oral Administration

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

What is the right dose? The elusive optimal biologic dose in phase I clinical trials. / Adjei, Alex.

In: Journal of Clinical Oncology, Vol. 24, No. 25, 01.09.2006, p. 4054-4055.

Research output: Contribution to journalEditorial

@article{23e79c0e39234904a08e90c8594636e1,
title = "What is the right dose? The elusive optimal biologic dose in phase I clinical trials",
author = "Alex Adjei",
year = "2006",
month = "9",
day = "1",
doi = "10.1200/JCO.2006.07.4658",
language = "English (US)",
volume = "24",
pages = "4054--4055",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "25",

}

TY - JOUR

T1 - What is the right dose? The elusive optimal biologic dose in phase I clinical trials

AU - Adjei, Alex

PY - 2006/9/1

Y1 - 2006/9/1

UR - http://www.scopus.com/inward/record.url?scp=33748652419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748652419&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.07.4658

DO - 10.1200/JCO.2006.07.4658

M3 - Editorial

C2 - 16943522

AN - SCOPUS:33748652419

VL - 24

SP - 4054

EP - 4055

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 25

ER -